RBC Capital analyst Shagun Singh initiated coverage of Tandem Diabetes with an Outperform rating and $65 price target The firm sees “significant upside potential” driven by earnings revisions and multiple expansion. It projects earnings upside driven by Mobi adoption, continuous glucose monitoring integration, and Type 2 indication expansion to aid new patient adds and pump renewals. Channel checks and analyses suggest weight loss drugs should not derail Tandem’s global pump opportunity as it is “vastly underpenetrated,” the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TNDM:
- Citi opens ‘negative catalyst watch’ on Tandem Diabetes into earnings
- App data suggests potential Q3 shipment beat from Tandem, says Morgan Stanley
- TJX downgraded, Crocs upgraded: Wall Street’s top analyst calls
- Tandem Diabetes initiated with an Equal Weight at Morgan Stanley
- Street analysts say diabetes stocks “overreacting” to Lilly GLP-1 study results